Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Class A ordinary share, par value $0.0001 per share
-
Shares outstanding
-
71,400,541
-
Total 13F shares
-
62,105,859
-
Share change
-
+1,441,004
-
Total reported value
-
$3,131,140,770
-
Put/Call ratio
-
67%
-
Price per share
-
$50.42
-
Number of holders
-
108
-
Value change
-
+$81,133,174
-
Number of buys
-
69
-
Number of sells
-
41
Institutional Holders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) as of Q3 2024
As of 30 Sep 2024,
MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) was held by
108 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,105,859 shares.
The largest 10 holders included
BVF INC/IL, Cormorant Asset Management, LP, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Avoro Capital Advisors LLC, CITADEL ADVISORS LLC, Holocene Advisors, LP, GOLDMAN SACHS GROUP INC, WESTFIELD CAPITAL MANAGEMENT CO LP, and MARSHALL WACE, LLP.
This page lists
108
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.